Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1969 3
1970 3
1971 2
1975 4
1976 1
1977 6
1978 1
1979 1
1980 4
1981 2
1982 3
1983 2
1984 2
1985 3
1986 3
1987 1
1989 1
1992 1
1998 1
2005 1
2006 3
2007 3
2008 2
2009 3
2010 5
2011 1
2012 4
2013 3
2014 6
2015 7
2016 12
2017 7
2018 9
2019 8
2020 16
2021 8
2022 5
2023 6
2024 13
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for giuli c
Search for Ciuli C instead (1 results)
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Nov 22;79(5):1242-1257. doi: 10.1093/cid/ciae228. Clin Infect Dis. 2024. PMID: 38663013 Free PMC article.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512 Free PMC article.
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data.
Piselli P, Tavelli A, Cimaglia C, Muccini C, Bandera A, Marchetti GC, Torti C, Mazzotta V, Pipitò L, Caioli A, Girardi E, Antinori A, Serraino D, d'Arminio Monforte A, Cingolani A; Icona Foundation Study Group. Piselli P, et al. Int J Cancer. 2025 Sep 15;157(6):1142-1153. doi: 10.1002/ijc.35493. Epub 2025 May 29. Int J Cancer. 2025. PMID: 40437996 Free PMC article.
miR-132-3p is down-regulated in plasma and CD171+ extracellular vesicles isolated from patients with mild Alzheimer's disease.
Sbriscia M, Spadoni T, Ambrogini P, Guescini M, Agostini R, Graciotti L, Piacenza F, Giuli C, Cecati M, Bonfigli AR, Vaiasicca S, Pagliarini M, Rusanova I, Fazioli F, Sabbatinelli J, Albertini MC, Olivieri F, Giuliani A. Sbriscia M, et al. Among authors: giuli c. Mech Ageing Dev. 2025 Jun;225:112063. doi: 10.1016/j.mad.2025.112063. Epub 2025 Apr 17. Mech Ageing Dev. 2025. PMID: 40252983 Free article.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Jun 3;79(6):1279-1288. doi: 10.1093/jac/dkae081. J Antimicrob Chemother. 2024. PMID: 38581349 Free article.
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, Cervo A, Carrozzo G, Saracino A, Rusconi S, Marchetti G, Ceccherini-Silberstein F, Antinori A, d'Arminio Monforte A, Muccini C; Icona Foundation Study Group. Gagliardini R, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2169-2178. doi: 10.1093/jac/dkaf184. J Antimicrob Chemother. 2025. PMID: 40570134 Free PMC article.
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation.
Mussini C, Giacomelli A, Quiros-Roldan E, Mazzotta V, Di Biagio A, De Vito A, Costantini A, D'Ettorre G, Giacometti A, Vergori A, Tavelli A, Malagnino V, Castagna A, Chester J, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Cohort Study for the Icona Foundation Study Group. Mussini C, et al. EClinicalMedicine. 2025 Jul 24;86:103368. doi: 10.1016/j.eclinm.2025.103368. eCollection 2025 Aug. EClinicalMedicine. 2025. PMID: 40740293 Free PMC article.
160 results